Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Twist Bioscience (Nasdaq: TWST) has announced a collaboration with Vivlion GmbH to develop CRISPR gRNA libraries for various applications in genome engineering and drug development. This partnership leverages Twist's high-quality synthetic DNA production capabilities and Vivlion's innovative 3Cs technology for creating uniform CRISPR libraries. The collaboration aims to enhance genomic research efficiency, enabling faster gene function analysis. The joint effort is expected to significantly impact R&D in functional genomics.
Twist Bioscience Corporation (NASDAQ: TWST) has announced plans to release its financial results for the fiscal 2021 second quarter on May 6, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. The financial results will be accessible on the company's website under Investor Relations. Twist Bioscience is focused on pioneering DNA synthesis technology, catering to diverse industries including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) has expanded its lease for the 'Factory of the Future' near Portland, Oregon, adding approximately 100,000 square feet to its existing 110,000-square-foot facility. This expansion supports the company's planned growth in synthetic DNA, including potential verticals like DNA data storage. CEO Emily M. Leproust emphasized the need for strategic space planning for future market opportunities. The financial commitment for the expansion begins in 2022, aiming to bolster Twist’s capabilities in synthetic biology and genomics.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a partnership with Pure Biologics to enhance the discovery of immuno-oncology antibody-based drugs. Through this collaboration, Twist Biopharma will provide Pure Biologics with access to synthetic antibody phage display libraries, optimized with advanced techniques including AI and big data analytics. The partnership aims to identify and optimize novel antibody candidates for therapeutic applications, with Pure Biologics committing to annual technology access fees and future milestone payments for successful outcomes.
Twist Bioscience (TWST) announced it will acquire rights to a GPCR library and proprietary Twist Antibody Optimization software developed with Distributed Bio. This acquisition, initiated in 2016, enhances Twist's capabilities in antibody discovery using its silicon DNA synthesis platform. The GPCR library contributes to a 'Library of Libraries' with over 10 billion antibodies, facilitating optimized therapeutics. The financial terms remain undisclosed, and the move supports Twist's growth in synthetic biology and genomics, aiming to advance drug discovery and development.
AcornMed Biotechnology has announced a partnership with Twist Bioscience to integrate Twist's next generation sequencing (NGS) target enrichment and library preparation panels into AcornMed's cancer precision medicine tests. This collaboration aims to enhance genetic analysis for better treatment strategies. Dr. Feng Lou, CTO of AcornMed, emphasized the importance of Twist's quality DNA synthesis in improving diagnostic accuracy. The partnership is expected to positively influence patient treatment and healthcare costs in China.
Twist Bioscience (NASDAQ: TWST) has partnered with Stanford University's Innovative Medicines Accelerator to provide access to its antibody discovery services and its innovative 'Library of Libraries.' This collaboration will enable Stanford researchers to utilize Twist’s advanced synthetic antibody libraries for various therapeutic targets. Twist will receive technology access fees and share in revenue from outlicensed antibodies. The first project aims to discover novel antibodies targeting a neuroscience application. The partnership showcases Twist's commitment to advancing biologics discovery through collaboration.
Twist Bioscience (TWST) has been awarded the Great Place to Work® Certification™, an accolade based on employee feedback regarding workplace culture and experience. This certification signifies Twist's commitment to fostering a positive work environment, even during challenges like the global pandemic. CEO Emily M. Leproust highlighted the importance of employees in driving growth and success. Twist offers competitive compensation, employee development, and robust family-friendly policies. The company specializes in synthetic DNA technology, impacting multiple sectors including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) has entered into a partnership with Kyowa Kirin Pharmaceutical Research, Inc. to discover novel antibodies targeting an undisclosed G protein-coupled receptor (GPCR). This collaboration utilizes Twist's unique 'Library of Libraries' for biologics discovery, enabling rapid antibody development. The partnership aims to enhance the efficiency and success rate of antibody therapeutics, leveraging Twist's scalable DNA manufacturing capabilities. An upfront payment was received, with Kyowa Kirin holding an option for development and commercial rights.
Twist Bioscience Corporation and Biotia have received Emergency Use Authorization (EUA) from the FDA for their SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. This in vitro diagnostic test is designed to detect SARS-CoV-2 RNA with high sensitivity and analyze the entire viral RNA sequence, allowing for the identification of genetic variants. This assay is significant amid rising concerns over new viral mutations. The test enables batch processing of samples, enhancing public health responses against COVID-19. It is expected to be available for purchase soon.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
